NASDAQ:AXLA Axcella Health (AXLA) Stock Price, News & Analysis → A new way to collect income from stocks (From DTI) (Ad) Free AXLA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.36▼$0.5150-Day Range$0.40▼$4.5852-Week Range$0.34▼$41.25Volume6,700 shsAverage Volume267,009 shsMarket Capitalization$1.18 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaStock AnalysisEarningsHeadlinesInsider TradesOwnershipShort InterestSocial Media Get Axcella Health alerts: Email Address Ad DTIthe harsh reality of the stock marketOK, you’re not supposed to say this In fact, maverick investor Graham Lindman says it’s become the silent elephant in the room that everyone is pretending isn’t there. But he just said it: Most stocks suck. And he isn’t saying that figuratively or subjectively… You see, 96% of stocks underperform. Just 4% of “Apex Stocks” generate virtually all the wealth.All you have to do is watch here for all the details. About Axcella Health Stock (NASDAQ:AXLA)Axcella Health Inc. operates as a clinical-stage biotechnology company in the United States. The company treats complex diseases using endogenous metabolic modulators. Its product pipeline includes AXA1125 that is in Phase 2a clinical trial for long COVID therapy for patients, as well as Phase 2b clinical trial for treating non-alcoholic steatohepatitis; and AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.Read More Ad DTIthe harsh reality of the stock marketOK, you’re not supposed to say this In fact, maverick investor Graham Lindman says it’s become the silent elephant in the room that everyone is pretending isn’t there. But he just said it: Most stocks suck. And he isn’t saying that figuratively or subjectively… You see, 96% of stocks underperform. Just 4% of “Apex Stocks” generate virtually all the wealth.All you have to do is watch here for all the details. AXLA Stock News HeadlinesDecember 27, 2023 | bizjournals.comBiotech layoffs 2023: In Q4, 11 companies laid off around 500 peopleDecember 25, 2023 | bizjournals.comYear in Review: Here are the top stories in Boston-area life sciences in 2023April 24, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.December 5, 2023 | msn.comAxcella Health to closeDecember 5, 2023 | bizjournals.comFlagship spinout Axcella collapses, leaving future of its long Covid drug uncertainNovember 7, 2023 | morningstar.comAxcella Health Inc AXLANovember 1, 2023 | msn.comAxcella Health (AXLA) Price Target Increased by 7971.00% to 15,870.09September 29, 2023 | markets.businessinsider.comPre-market Movers: RLMD, BROG, VSME, AXLA, NKE…April 24, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…September 15, 2023 | finance.yahoo.comAre Medical Stocks Lagging Axcella Health (AXLA) This Year?September 15, 2023 | finance.yahoo.comAre Medical Stocks Lagging Axcella Health (AXLA) This Year?September 15, 2023 | investorplace.comWhy Is Axcella Health (AXLA) Stock Down 24% Today?September 15, 2023 | msn.comFord, GM shares fall on strike action, with ARM stock jumping post IPO and other shares on the moveSeptember 14, 2023 | finance.yahoo.comAxcella Announces Reverse Stock Split Effective September 19, 2023September 5, 2023 | benzinga.comPenny Stocks Stocks Poised To Pop On News (EPAZ, AXLA, NVOS, IQST)August 30, 2023 | finance.yahoo.comAre Medical Stocks Lagging Clover Health Investments (CLOV) This Year?August 30, 2023 | benzinga.comWhat's Going On With Axcella Health Stock This Week?August 30, 2023 | finance.yahoo.comAxcella (AXLA) Up on Patent Grant for Long Covid Fatigue DrugAugust 30, 2023 | finance.yahoo.comAre Medical Stocks Lagging Clover Health Investments (CLOV) This Year?August 29, 2023 | benzinga.comAxcella Health Stock Is Skyrocketing: What's Going On?August 29, 2023 | proactiveinvestors.comAxcella Health stock rockets on long Covid patent winAugust 29, 2023 | finance.yahoo.comAxcella Granted Patent for Long COVID Fatigue TreatmentAugust 29, 2023 | investorplace.comWhy Is Axcella Health (AXLA) Stock Up 280% Today?May 8, 2023 | markets.businessinsider.comAxcella Health (AXLA) Gets a Hold from H.C. WainwrightApril 17, 2023 | finance.yahoo.comAxcella Announces Two Oral Presentations on AXA1125 for Long COVID Fatigue at ECCMID 2023April 14, 2023 | finance.yahoo.comBig Bank's Big Q1 Performance, Florida Gov. Quietly Slips 6-Week Abortion Ban Into Law, Subway Sandwich Seeks $10B Sale: Today's Top StoriesApril 14, 2023 | msn.comLong COVID-Fatigue Impacts 50M People - Axcella Health Seeks Funding To Support Drug DevelopmentSee More Headlines Receive AXLA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Axcella Health and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today4/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:AXLA CUSIPN/A CIK1633070 Webwww.axcellahealth.com Phone(857) 320-2200Fax617-441-6243Employees11Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($19.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-81,190,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-259.91% Debt Debt-to-Equity RatioN/A Current Ratio0.80 Quick Ratio0.80 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.42 per share Price / Book0.28Miscellaneous Outstanding Shares2,950,000Free Float2,883,000Market Cap$1.18 million OptionableOptionable Beta0.46 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Craig R. Jalbert CIRA (Age 61)President, CEO, Treasurer, Secretary, Financial and Accounting Officer & Director Dr. Alison D. Schecter M.D. (Age 58)President of Strategy & Operations Comp: $525.53kMr. David R. Epstein B.Sc. (Age 61)M.B.A., Consultant Comp: $228.34kMr. Dan KirbySenior Vice President of Strategic OperationsMarie WashburnVP of Finance & Corporate ControllerDr. Karim Azer Ph.D.Vice President of Platform & DiscoveryMore ExecutivesKey CompetitorsTC BiopharmNASDAQ:TCBPSQZ BiotechnologiesNYSE:SQZScinai ImmunotherapeuticsNASDAQ:SCNIAcorda TherapeuticsNASDAQ:ACORAcorda TherapeuticsNASDAQ:ACORQView All Competitors AXLA Stock Analysis - Frequently Asked Questions How were Axcella Health's earnings last quarter? Axcella Health Inc. (NASDAQ:AXLA) posted its quarterly earnings data on Wednesday, November, 10th. The company reported ($10.25) EPS for the quarter, topping the consensus estimate of ($11.25) by $1.00. When did Axcella Health's stock split? Shares of Axcella Health reverse split on the morning of Tuesday, September 19th 2023. The 1-25 reverse split was announced on Thursday, September 14th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What is Bill Hinshaw's approval rating as Axcella Health's CEO? 5 employees have rated Axcella Health Chief Executive Officer Bill Hinshaw on Glassdoor.com. Bill Hinshaw has an approval rating of 100% among the company's employees. This puts Bill Hinshaw in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 77.0% of employees surveyed would recommend working at Axcella Health to a friend. What other stocks do shareholders of Axcella Health own? Based on aggregate information from My MarketBeat watchlists, some companies that other Axcella Health investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Evofem Biosciences (EVFM), ADMA Biologics (ADMA), Coty (COTY), Energy Transfer (ET), Myovant Sciences (MYOV), NVIDIA (NVDA), Pfizer (PFE) and Moderna (MRNA). When did Axcella Health IPO? Axcella Health (AXLA) raised $76 million in an initial public offering (IPO) on Thursday, May 9th 2019. The company issued 3,600,000 shares at $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and SVB Leerink served as the underwriters for the IPO. This page (NASDAQ:AXLA) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe Greatest Bull Market in Crypto History…Weiss RatingsUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Axcella Health Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
